Diabetes Mellitus: Pharmacotherapy-Sulfonyl Ureas!

PHARMACOTHERAPY

Oral and injectable agents are available to treat patients with T2DM who are unable to achieve glycemic control through meal planning and physical activity.

Medications classifications include:

Sulfonyl Urea's
Nonsylfonylurea Secretagogues (a-Glinides)
Biguanides
Thiazolidinediones
a-Glucosidase Inhibitors
Dipeptidyl Peptidase-4 Inhibitors(Gliptins)
Sodium-glucose co-transporter (SGLT) Inhibitors
Central-Acting Dopamine Agonists
Bile Acid Sequestrants
Insulin therapy

SULFONYL UREAS

Sulfonylureas represent the first class of Oral blood glucose lowering agents approved by the United States.
These drugs are classified as either First- or Second-Generation drugs.
Both classes of sulfonyl ureas are effective when given at equipotent doses.

Mechanism of Action

Sulfonyl ureas enhance insulin secretion by blocking ATP-sensitive potassium channels in the cell membranes of pancreatic beta cells. This action results in membrane depolarization, allowing the influx of calcium to cause the translocation of secretory granules of Insulin to the cell surface and enhances insulin secretion in a non-glucose dependent manner.

Metabolism

All sulfonyl ureas undergo hepatic biotransformation with most agents being metabolized by Cytochrome-P450 2C9 Pathway.
The first-generation sulfonyl ureas are most likely to cause drug interaction than the second-generation ones.
All sulfonyl ureas except Tolbutamide require dose adjustment or are not recommended for renal impairment.

Clinical Use

Sulfonyl ureas blood-glucose lowering agents can be observed in both Fasting and post-prandial levels.

Therapy

Monotherapy with these agents generally produce a 1.5-2% decline in A1c levels. and a 60-70mg/dL reduction in Fasting blood glucose levels (FBG).

Adverse Drug Reactions

Hypoglycemia
Weight Gain
Sulfa allergy

**ONLY SULFONYL UREAS THAT DOESNOT REQUIRE DOSE ADJUSTMENTS IS TOLBUTAMIDE**

Comments

Drug-Induced Ototoxicity!

DRUG-INDUCED OTOTOXICITY What is drug Induced Ototoxicity? Drug-Induced ototoxicity can affect hearing (auditory or cochlear function0, balance (vestibular function) depending on the drug. Drugs of almost every class have been reported to produce tinnitus (sounds in ear), as have placebos. The following agents are associated with measurable changes in hearing or vestibular defect when administered systemically. 1. AMINOGLYCOSIDES: Aminoglycosides antibiotics can cause cochlear or vestibular toxicities. Cochlear toxicity: occurs as progressive hear loss, starting with highest tones and advancing to lower tones. Thus, considerable damage can occur before the patient recognizes it. S ymptoms of Vestibular damage : include; Dizziness Vertigo Ataxia Both forms of ototoxicity are bilateral and potentially reversible, but permanent damage is common and can progress even after discontinuation of aminoglycosides. Clinically detectable ototoxicity in as many as 5% patients. Most amin...

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

PHARMACOTHERAPY: Medications classifications include: Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions. Clinical Use: FPG concentrations have been decreased by 40-5...

Myocardial Infarction- Etiology, Pathogenesis, Clinical Diagnosis and Management!

MYOCARDIAL INFARCTION Definition: Myocardial Infarction is defined as " a diseased condition which is caused by reduced blood flow to the coronary artery due to atherosclerosis and occlusion of artery by embolus or thrombus." Myocardial Infarction (or Heart attack) is the irreversible damage of myocardial tissue due to prolonged ischemia or hypoxia. Universally accepted definition of MI: Evidence of myocardial necrosis in consistent with the myocardial ischemia, in which case any of the following meets the diagnosis of Myocardial Infarction. Evidence rises and/or fall of cardiac biomarkers (preferably troponin). ECG changes indicative of new ischemia (new ST-T changes or new left bundle branch block) Development of pathological Q waves. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. Etiology: Tobacco smoking Diabetes Mellitus Age Hypertension Obesity Gender Stress Drug abuse Alcohol consumption Family history of ischemic heart dise...

Medical Concepts

Search This Blog